IFM Due Inc. has patented stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer.

TYK Medicines Inc. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.

Shanghai Ringene Biopharma Co. Ltd. has disclosed son of sevenless homolog (SOS1) inhibitors reported to be useful for the treatment of cancer.

Annexon Inc. has identified boronic acid derivatives acting as complement C1s subcomponent inhibitors reported to be useful for the treatment of neurodegeneration, inflammatory, eye, metabolic and autoimmune diseases.

Oncovalent Therapeutics Inc. has patented SUMO-activating enzyme subunit 1 (SAE1) inhibitors reported to be useful for the treatment of cancer.

Guangzhou Lupeng Pharmaceutical Co. Ltd. and Newave Pharmaceutical LLC have divulged (mutant) ligands reported to be useful for the treatment of cancer, autoimmune disease and inflammation.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.

Shanghai Lisen Imprinting Pharmaceutical Technology Co. Ltd. has disclosed EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of small-cell lung (SCLC) and l lung cancer (NSCLC).

Researchers from Acerand Therapeutics (Hong Kong) Ltd. have presented Poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer, metabolic diseases, cardiovascular, inflammatory, psychiatric and immunological disorders.

Nanjing Zaiming Pharmaceutical Co. Ltd. has identified DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.